All ProductsDisplaying Products by Catalog Number (6300 - 6399)
0100020003000400050006000700080009001000110012001300140015001600170018001900200021002200230024002500260027002800290030003100320033003400350036003700380039004000410042004300440045004600470048004900500051005200530054005500560057005800590060006100620063006400650066006700680069007000710072007300740075007600770078007900800081008200830084008500860087008800
| Cat. No. | Product Name / Activity |
|---|---|
| 6300 | Thalidomide 4'-oxyacetamide-alkylC4-azide |
| Cereblon ligand with alkyl linker and terminal azide for onward chemistry | |
| 6301 | Parathyroid hormone (1-34) (rat) |
| Parathyroid hormone (PTH) receptor agonist | |
| 6302 | Pomalidomide |
| Cereblon binder; also TNF-α inhibitor and antiangiogenic | |
| 6304 | BigLEN (mouse) |
| GPR171 agonist | |
| 6305 | Lenalidomide |
| Cereblon binder; induces ubiquitination and degradation of CK1α by E3 ubiquitin ligase | |
| 6308 | PEN (mouse) |
| GPR83 agonist | |
| 6310 | AZD 1208 |
| Potent pan Pim kinase inhibitor | |
| 6311 | Tadalafil |
| Potent and highly selective PDE5 inhibitor; orally bioavailable | |
| 6313 | A 33 |
| Potent and selective PDE4B inhibitor | |
| 6315 | DMNB-caged-Serine |
| Caged serine; excited by visible blue light | |
| 6316 | ASB 14780 |
| Potent and selective cytosolic phospholipase A2 alpha (cPLA2α) inhibitor; active in vivo; orally bioavailable | |
| 6317 | Prasugrel |
| Irreversible P2Y12 antagonist; antiplatelet and orally active | |
| 6318 | Azimilide dihydrochloride |
| Kv11.1 (hERG) channel blocker | |
| 6319 | CBM 301940 |
| Potent malonyl-CoA decarboxylase inhibitor; orally bioavailable | |
| 6320 | ESI 05 |
| Epac2 inhibitor | |
| 6321 | 10-Cl-BBQ |
| Potent aryl hydrocarbon receptor (AhR) agonist; orally bioavailable | |
| 6322 | LW 6 |
| Malate dehydrogenase-2 (MDH2) inhibitor; also inhibits HIF-1α | |
| 6323 | FX 1 |
| Bcl-6 inhibitor; 10-fold more potent than endogenous Bcl-6 corepressors | |
| 6324 | Autophinib |
| Potent VPS34 inhibitor | |
| 6327 | dBET1 |
| (+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo | |
| 6329 | Clozapine N-oxide dihydrochloride |
| Activator of hM3Dq and hM4Di DREADDs; water soluble version of Clozapine N-oxide (Cat. No. 4936) | |
| 6330 | AZ 5704 |
| Potent and selective ATM kinase inhibitor; orally bioavailable | |
| 6332 | Atosiban |
| Potent oxytocin receptor antagonist | |
| 6333 | Phosphoramidon disodium salt |
| Neutral endopeptidase and endothelin converting enzyme inhibitor | |
| 6334 | THDOC |
| Positive modulator of GABAA receptors; endogenous neurosteroid | |
| 6336 | Trazodone hydrochloride |
| 5-HT2A and α1 adrenoceptor antagonist; also enhances neural differentiation; antidepressant and neuroprotectant | |
| 6340 | Epiblastin A |
| CK1 inhibitor; converts epiblast stem cells to ESCs and promotes ESC self-renewal | |
| 6341 | INF 39 |
| Irreversible NLRP3 inhibitor | |
| 6342 | Tamoxifen |
| Estrogen receptor partial agonist/antagonist | |
| 6343 | Rosuvastatin calcium |
| Potent HMG-CoA reductase inhibitor | |
| 6344 | OUL 35 |
| Selective PARP-10 inhibitor | |
| 6346 | PF 5006739 |
| Potent CK1δ/ε inhibitor | |
| 6347 | PF 04628935 |
| Potent ghrelin receptor inverse agonist | |
| 6348 | PF 06424439 |
| Potent and selective DGAT2 inhibitor | |
| 6349 | Pelitinib |
| Potent and irreversible EGFR inhibitor; orally bioavailable | |
| 6350 | PF 05190457 |
| High affinity and selective ghrelin receptor inverse agonist | |
| 6351 | (R)-ZINC 3573 |
| MRGPRX2 agonist | |
| 6353 | UoS 12258 |
| Positive allosteric modulator of AMPA receptors | |
| 6354 | CNV Dopamine |
| Caged dopamine; photolysed by UV light | |
| 6355 | VU 0650991 |
| Non-competitive GLP-1 antagonist; orally bioavailable and brain penetrant | |
| 6356 | AT 1 |
| (+)-JQ1 based PROTAC® with selectivity for BRD4 | |
| 6357 | Ciclesonide |
| Glucocorticoid antiasthmatic prodrug | |
| 6359 | Nelarabine |
| Purine nuceloside analog; inhibits DNA synthesis | |
| 6362 | GSK 143 |
| Syk inhibitor | |
| 6363 | Avagacestat |
| Highly potent γ-secretase inhibitor; orally bioavailable | |
| 6364 | Squarunkin A hydrochloride |
| UNC119 chaperone-cargo interaction inhibitor; disrupts Src activation | |
| 6367 | Z 944 |
| CaV3.x blocker | |
| 6369 | GNE 9278 |
| Positive allosteric modulator of NMDA receptors; acts in transmembrane domain | |
| 6370 | Nor NOHA monoacetate |
| Arginase inhibitor | |
| 6372 | PSB CB5 |
| Selective GPR18 antagonist | |
| 6374 | PF 04457845 |
| Potent and selective irreversible FAAH inhibitor | |
| 6377 | DIM-C-pPhOH |
| Nur77 antagonist | |
| 6378 | JMS 17-2 hydrochloride |
| CX3CR1 antagonist | |
| 6383 | SR 16832 |
| Dual site PPARγ inhibitor | |
| 6384 | Ciclopirox |
| Pan-histone demethylase inhibitor | |
| 6387 | A 485 |
| Potent and selective p300/CBP inhibitor; orally bioavailable | |
| 6390 | SAG dihydrochloride |
| Dihydrochloride salt of SAG; Smo receptor agonist | |
| 6391 | CD38 inhibitor 78c |
| Potent CD38 inhibitor; active in vivo | |
| 6392 | B02 |
| RAD51 recombinase inhibitor | |
| 6398 | SKA 121 |
| Positive allosteric modulator of KCa3.1 (IK) channels |